tak-925
Small moleculeexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 7, 2017 (NCT03332784)
Timeline
Indications
Mechanism of action
- Orexin receptorAGONIST
Orexin receptor agonist
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)N1CCC[C@H](NS(C)(=O)=O)[C@@H]1CO[C@H]1CC[C@@H](c2ccccc2)CC1- Mol. weight
- 424.56 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650341 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05814016 | Phase 2 | May 25, 2023 | Takeda |
| NCT05180890 | Phase 1 | Mar 10, 2022 | Takeda |
| NCT05025397 | Phase 1 | Sep 28, 2021 | Takeda |
| NCT04091438 | Phase 1 | Feb 12, 2020 | Millennium Pharmaceuticals, Takeda |
| NCT04091425 | Phase 1 | Oct 26, 2019 | Millennium Pharmaceuticals, Takeda |
| NCT03748979 | Phase 1 | Nov 21, 2018 | Takeda |
| NCT03522506 | Phase 1 | May 16, 2018 | Takeda |
| NCT03332784 | Phase 1 | Nov 7, 2017 | Takeda |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 8 | 6 | 2 | 2017 |
| Millennium Pharmaceuticals | For profit | 2 | 2 | 1 | 2019 |
2 organizations
Page 1 / 1